Long-Acting Injectable Antipsychotics Industry Trends and Preclinical Development Challenges
Summary
Long-acting injectable (LAI) antipsychotics represent an important advancement in schizophrenia treatment by addressing challenges associated with medication adherence and long-term disease management.
Recent industry developments, including Johnson & Johnson's exclusive marketing partnership with Lingyao Health for its paliperidone palmitate LAI antipsychotics in mainland China, reflect continued interest in and development of long-acting treatment approaches.
As LAI formulations continue to advance, their development introduces unique preclinical requirements beyond conventional oral formulations. Drug developers must address challenges associated with long-term efficacy evaluation, sustained drug exposure, pharmacokinetic/pharmacodynamic (PK/PD) relationships, and safety assessment.
This article discusses emerging trends in LAI antipsychotic development, key scientific challenges, and preclinical strategies that can support more reliable translation in schizophrenia drug discovery.
Industry Trend: Growing Adoption of Long-Acting Injectable Antipsychotics
Long-acting injectable antipsychotics have gained increasing attention as an important therapeutic approach for improving treatment continuity and supporting long-term schizophrenia management.
In April 2026, Johnson & Johnson announced a strategic agreement with Beijing Lingyao Health Services (a subsidiary of SPI Pharma), granting exclusive marketing rights in mainland China for its paliperidone palmitate LAI antipsychotics, including INVEGA SUSTENNA®, INVEGA TRINZA®, and XEPLION®.
This agreement reflects the continued development of long-acting treatment strategies in schizophrenia care. Compared with daily oral administration, LAI formulations provide sustained drug exposure and may help address challenges associated with medication adherence and relapse prevention.
The expanding adoption of LAI therapies highlights the need for preclinical evaluation approaches capable of characterizing sustained pharmacological effects and supporting the development of next-generation antipsychotic treatments.
Fig. 1 Summary of efficacy, safety, and target population of long-acting injectable antipsychotics in early psychosis. (Etienne, M. & Verdoux, H., 2025)
Scientific Background: The Role of LAI Formulations in Schizophrenia Treatment
Schizophrenia is a complex psychiatric disorder requiring long-term therapeutic management. Although antipsychotic medications remain the cornerstone of treatment, maintaining consistent medication exposure and improving adherence continue to represent major clinical challenges.
LAI formulations were developed to provide prolonged drug release and more stable exposure profiles compared with conventional oral therapies. Clinical evidence suggests that LAI antipsychotics can support treatment continuity and may help reduce relapse risks associated with poor medication adherence.
However, the sustained-release characteristics of LAI formulations also introduce additional development considerations. Unlike short-acting compounds, LAI programs require a comprehensive understanding of drug absorption, distribution, exposure duration, pharmacodynamic effects, and long-term safety profiles.
Therefore, appropriate preclinical models and evaluation strategies are essential for better characterizing therapeutic potential before clinical development.
Development Challenges in Long-Acting Injectable Antipsychotic Programs
While LAI formulations offer important clinical advantages, their development presents several unique preclinical challenges.
Extended In Vivo Efficacy Evaluation
Long-acting formulations require longer observation periods to reflect clinical dosing intervals, such as monthly or three-month administration schedules. Traditional short-term efficacy studies may not fully capture the duration of action or sustained therapeutic effects of LAI compounds. Preclinical evaluation strategies should therefore incorporate longitudinal study designs capable of monitoring efficacy maintenance over extended periods. Disease-relevant schizophrenia models combined with repeated behavioral and pharmacodynamic assessments can provide valuable insights into the durability of therapeutic responses.
Complex PK/PD Relationships
Understanding the relationship between sustained drug release, systemic exposure, brain distribution, and pharmacodynamic effects is a critical component of LAI development. Compared with immediate-release formulations, LAI products exhibit distinct absorption and exposure characteristics. Conventional short-term PK/PD studies may therefore provide limited information regarding long-term exposure-response relationships. Integrated PK/PD evaluation strategies, including plasma and brain drug concentration monitoring combined with pharmacodynamic endpoints, can help characterize formulation performance and support development decisions.
Long-Term Safety Assessment Requirements
Extended drug exposure introduces additional safety considerations, including injection site reactions, potential accumulation-related toxicity, and immune-related responses. Comprehensive preclinical safety evaluation is required to characterize tolerability and identify potential risks associated with prolonged administration. Integrating safety assessments with efficacy and pharmacological evaluations can provide a more complete understanding of candidate performance.
Need for More Translational Schizophrenia Models
As schizophrenia therapies continue to evolve, preclinical models must provide meaningful insights into disease-relevant mechanisms and therapeutic responses. No single animal model can capture all aspects of schizophrenia. Instead, different models may address specific biological mechanisms or disease-associated phenotypes. Models should be selected based on research objectives and therapeutic mechanisms, with consideration of relevant domains including positive symptoms, negative symptoms, social dysfunction, and cognitive impairment.
Preclinical Solutions: Supporting Translational Development of LAI Antipsychotics
Addressing the challenges associated with LAI development requires integrated preclinical strategies combining disease-relevant models, longitudinal evaluation, and mechanism-based assessments.
Disease-Relevant Schizophrenia Models
Preclinical schizophrenia research may incorporate multiple model types depending on research objectives and therapeutic mechanisms, including pharmacologically induced models (e.g., MK-801 and PCP), genetically modified models, and neurodevelopmental models. These approaches enable researchers to investigate different aspects of schizophrenia biology and evaluate candidate compounds according to specific therapeutic hypotheses.
Longitudinal Pharmacodynamic Evaluation
Long-acting formulations require evaluation strategies capable of characterizing sustained therapeutic effects over extended periods. Multidimensional behavioral assessment approaches, including prepulse inhibition, open field testing, social interaction assays, and cognitive behavioral assessments, can provide complementary efficacy readouts.
Multi-timepoint sampling strategies can further support evaluation of efficacy duration and exposure-response relationships.
Integrated PK/PD and Mechanism-Based Assessment
Combining pharmacokinetic monitoring with pharmacodynamic measurements provides insights into sustained-release behavior and therapeutic effects. Mechanistic studies incorporating neural circuit analysis, electroencephalography (EEG), neurotransmitter assays, and other functional approaches can support understanding of drug mechanisms of action and improve translational interpretation.
Supporting Long-Acting Antipsychotic Development Through Integrated Preclinical Expertise
The development of innovative long-acting antipsychotics requires coordinated evaluation across disease models, efficacy assessment, PK/PD characterization, safety studies, and mechanism-focused research. Ace Therapeutics provides preclinical research support for psychiatric and CNS drug development programs, including schizophrenia models, behavioral efficacy evaluation, pharmacodynamic assessment, DMPK studies, and mechanism-of-action investigations.
By integrating disease-relevant models with multidimensional evaluation strategies, Ace Therapeutics supports researchers in generating relevant preclinical data to inform development decisions. Explore our virtual booth for additional insights, and contact our team to discuss your specific research goals.
References
- Smit, R., et al. Relapse in schizophrenia: The role of factors other than non-adherence to treatment. Early Intervention Psychiatry. 2024;18(9):710-719.
- Brissos, S., et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic Advances in Psychopharmacology. 2014;4(5):198-219.
- Pappa, S., et al. The evolution of long-acting antipsychotic treatments. Therapeutic Advances in Psychopharmacology. 2024.
- Etienne, M. & Verdoux, H. Impact of long-acting injectable antipsychotics in early psychosis: An umbrella review. Schizophrenia Research. 2025;277:140-150.
- Markowicz-Piasecka, M., et al. Long-acting injectable antipsychotics—a review on formulation and in vitro dissolution. Pharmaceutics. 2023;16(1):28.
